Conmed (CNMD) Reports In-Line Q2 EPS, Raises FY 2017 Revenue Guidance
Tweet
Share
E-mailGet Alerts CNMD Hot Sheet
Price: $33.06 -2.33%
EPS Growth %: -5.2%
Financial Fact:
Research and development expense: 8.35M
Today's EPS Names:
CRMT, REPL, HURC, More
EPS Growth %: -5.2%
Financial Fact:
Research and development expense: 8.35M
Today's EPS Names:
CRMT, REPL, HURC, More
Join SI Premium – FREE
Conmed (NASDAQ: CNMD) reported Q2 EPS of $0.41, in-line with the analyst estimate of $0.41. Revenue for the quarter came in at $197.15 million versus the consensus estimate of $194.5 million.
GUIDANCE:
Conmed sees FY2017 EPS of $1.85-$1.95, raises revenue for FY 2017 to 2-3% from 1-6% prior.
For earnings history and earnings-related data on Conmed (CNMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
- GitLab Inc (GTLB) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY Guidance
- Netskope, Inc. (NTSK) Tops Q1 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
